JP2025505687A5 - - Google Patents
Info
- Publication number
- JP2025505687A5 JP2025505687A5 JP2024547223A JP2024547223A JP2025505687A5 JP 2025505687 A5 JP2025505687 A5 JP 2025505687A5 JP 2024547223 A JP2024547223 A JP 2024547223A JP 2024547223 A JP2024547223 A JP 2024547223A JP 2025505687 A5 JP2025505687 A5 JP 2025505687A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- compound
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210119643.2 | 2022-02-09 | ||
| CN202210119643 | 2022-02-09 | ||
| US202263308883P | 2022-02-10 | 2022-02-10 | |
| US63/308,883 | 2022-02-10 | ||
| US202263328659P | 2022-04-07 | 2022-04-07 | |
| US63/328,659 | 2022-04-07 | ||
| US202363437718P | 2023-01-08 | 2023-01-08 | |
| US63/437,718 | 2023-01-08 | ||
| PCT/US2023/012734 WO2023154417A1 (en) | 2022-02-09 | 2023-02-09 | Morphic forms of cft7455 and methods of manufacture thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025505687A JP2025505687A (ja) | 2025-02-28 |
| JP2025505687A5 true JP2025505687A5 (cg-RX-API-DMAC7.html) | 2026-02-17 |
Family
ID=87565017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547223A Pending JP2025505687A (ja) | 2022-02-09 | 2023-02-09 | Cft7455のモルフィック形態及びその製造方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240391912A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4476217A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025505687A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240146048A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023216993A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3247460A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314625A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009897A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023154417A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| KR102947433B1 (ko) * | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6504034B2 (en) * | 2001-01-23 | 2003-01-07 | Hoffmann-La Roche Inc. | Naphthostyrils |
| CN111662226B (zh) * | 2015-01-28 | 2022-03-18 | 中国科学院广州生物医药与健康研究院 | 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物 |
| KR102947433B1 (ko) * | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| JP7629459B2 (ja) * | 2019-11-19 | 2025-02-13 | ブリストル-マイヤーズ スクイブ カンパニー | Heliosタンパク質の阻害剤として有用な化合物 |
| AU2021322285B2 (en) * | 2020-08-07 | 2026-08-13 | C4 Therapeutics, Inc. | Advantageous therapies for disorders mediated by Ikaros or Aiolos |
| CN118201612A (zh) * | 2021-08-04 | 2024-06-14 | 上海睿跃生物科技有限公司 | 用于治疗淋巴瘤的组合疗法的组合物和方法 |
| JP7807110B2 (ja) * | 2021-08-27 | 2026-01-27 | ハンチョウ グルビオ ファーマシューティカル カンパニー,リミティド | イソインドリノン化合物およびその使用 |
-
2023
- 2023-02-09 JP JP2024547223A patent/JP2025505687A/ja active Pending
- 2023-02-09 WO PCT/US2023/012734 patent/WO2023154417A1/en not_active Ceased
- 2023-02-09 AU AU2023216993A patent/AU2023216993A1/en active Pending
- 2023-02-09 CA CA3247460A patent/CA3247460A1/en active Pending
- 2023-02-09 EP EP23753451.6A patent/EP4476217A4/en active Pending
- 2023-02-09 KR KR1020247029748A patent/KR20240146048A/ko active Pending
- 2023-02-09 MX MX2024009897A patent/MX2024009897A/es unknown
- 2023-02-09 IL IL314625A patent/IL314625A/en unknown
-
2024
- 2024-08-07 US US18/797,261 patent/US20240391912A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538520A5 (cg-RX-API-DMAC7.html) | ||
| JP3662942B2 (ja) | 持続性放出甲状腺作用性組成物 | |
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| RU2314810C2 (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена | |
| JP2024074963A5 (cg-RX-API-DMAC7.html) | ||
| JPH06102622B2 (ja) | 肥満の治療 | |
| JP2022537551A5 (cg-RX-API-DMAC7.html) | ||
| RU2006109467A (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2017525713A5 (cg-RX-API-DMAC7.html) | ||
| JP2024517085A5 (cg-RX-API-DMAC7.html) | ||
| MX2012013014A (es) | Regimenes terapeuticos. | |
| CN110013478A (zh) | 用于抗肿瘤试剂施用的方法 | |
| RU2007101686A (ru) | Комбинированная композиция | |
| JP2008539273A5 (cg-RX-API-DMAC7.html) | ||
| Aufdemorte et al. | Modified topical steroid therapy for the treatment of oral mucous membrane pemphigoid | |
| JP2024514112A5 (cg-RX-API-DMAC7.html) | ||
| MX2026001173A (es) | Moduladores del potencial de receptor transitorio melastatina 3 (trpm3) para el tratamiento del dolor | |
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| JP2021530568A5 (cg-RX-API-DMAC7.html) | ||
| US20230414652A1 (en) | Composition and therapy for treatment of gag reflexes | |
| JP2023533472A5 (cg-RX-API-DMAC7.html) | ||
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
| TWI855501B (zh) | 治療方法 | |
| Demchuk et al. | Therapeutical application of transdermal systems that presented on us pharmaceutical market |